Our "anti-allergic benzocycloheptathiophene derivatives" was first authorized by the United States patent for invention and then authorized by China.



On March 29, 2016, the "anti-allergic benzocycloheptathiophene derivative" applied by our company through PCT international channels was granted invention patent authorization in the United States (patent number: US 9296731), and was granted Chinese invention patent authorization on April 6, 2016 (patent number: 201280031248.3). This marks a gratifying leap forward in our international independent intellectual property work.

"Anti-allergic benzocycloheptathiophene derivatives" is the material basis of the national class of new broad-spectrum anti-allergic drugs, rupatifen. It is a brand-new compound invented by Dr. Lin Tongjun, the chief scientist of our company. The new compound has the characteristics of enhancing drug efficacy and reducing side effects. It is superior to the existing anti-allergic drugs in many aspects and has a broad market prospect. The World Health Organization (WHO) lists allergic diseases as one of the three major diseases that need to be studied and prevented in the 21st century. According to statistics, the incidence of allergic diseases in my country is as high as 37.3. The market potential of anti-allergic drugs is huge, of which the global sales of allergic rhinitis drugs alone reached $6 billion. Therefore, once the compound is successfully researched and developed, it will provide a new drug with good therapeutic effect, wider indications and better safety for the majority of patients, and benefit mankind; it will change the market pattern of domestic anti-allergic drugs and bring good economic benefits to enterprises. The cumulative output value of the project is expected to exceed 10 billion yuan, and the profit and tax will exceed 1 billion yuan. For the Fujian pharmaceutical industry in the development stage, it is a shot in the arm.